Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real‐world evidence from the non‐interventional, prospective, German multicentre
PERSIST
study of patients with psoriasis after 1 year of treatment with guselkumab
Authors
Keywords
-
Journal
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-05-15
DOI
10.1111/jdv.18218
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guselkumab: Mid‐term effectiveness, drug survival and safety in real clinical practice
- (2021) Ricardo Ruiz‐Villaverde et al. Dermatologic Therapy
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
- (2021) Tiago Torres et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial
- (2021) Sascha Gerdes et al. JOURNAL OF DERMATOLOGY
- Guselkumab: Short‐term effectiveness and safety in real clinical practice
- (2020) Lourdes Rodriguez Fernandez‐Freire et al. Dermatologic Therapy
- A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
- (2020) J. Seneschal et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study
- (2020) A.‐C. Fougerousse et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Real‐life experience of guselkumab in patients with psoriasis
- (2020) Igor Snast et al. Dermatologic Therapy
- Long-term Single Center Experience in Treating Plaque Psoriasis With Guselkumab
- (2020) Khalad Maliyar et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
- (2020) Matteo Megna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care
- (2020) Neuza da Silva et al. PLoS One
- Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
- (2020) Marco Galluzzo et al. Journal of Clinical Medicine
- Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
- (2020) Kristian Reich et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
- (2019) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A safety evaluation of guselkumab for the treatment of psoriasis
- (2018) M. Galluzzo et al. Expert Opinion On Drug Safety
- Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies
- (2018) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”
- (2016) Anna Langenbruch et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- The German National Program on Psoriasis Health Care 2005–2015: results and experiences
- (2016) M. Augustin et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register
- (2015) I.Y.K. Iskandar et al. BRITISH JOURNAL OF DERMATOLOGY
- German psoriasis registry PsoBest: objectives, methodology and baseline data
- (2014) Matthias Augustin et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- US FDA patient-reported outcome guidance: great expectations and unintended consequences
- (2013) Sheri Fehnel et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Quality of life and sexual health in patients with genital psoriasis
- (2011) K.A.P. Meeuwis et al. BRITISH JOURNAL OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search